The 2nd annual World Orphan Drug Congress showcases drug development, new drug discovery and innovations related to rare diseases.
|
The World Orphan Drug Congress is the region’s most prestigious industry conference where ideas, intelligence and relationships really make a difference. It is an event that tackles all the key scientific and strategic issues facing the Orphan Drug industry, both today and in the future over a succinct 3-day programme. |
 |
|
The goal of the World Orphan Drugs Congress is to build a platform that bridges the scientific potential and the commercial reality of Orphan Drug indications, designations and market approach. It will tackle the critical strategic and commercial challenges associated with assigning resources to building viable and efficacious Orphan Drug candidates for a diverse range of incidences. |
 |
|
2010 speakers included: Protalix, INSERM/European Commission/World Health Organisation, BioMarin, Pharmacovigilance and Clinical Quality Assurance, Almac, Rare Diseases, Public Affairs and Market Access, GTC Biotherapeutics, Late Phase Solutions Europe AB, Actelion, Patheon, Kakkis EveryLife Foundation, Genzyme Corporation, Novartis, Centric Health Resources, EURORDIS, Dutch Steering Committee for Orphan Drugs, Trophos, Pfizer Inc, Genzyme Corporation, Eli Lilly, Strategic Product Development and Global Regulatory Affairs, Swedish Orphan Biovitrum, PTC Therapeutics, GlaxoSmithKline, Shire HGT, Celgene International, National Organisation for Rare Diseases (NORD), Prosensa, Patient Centred Solutions |
 |
The World Orphan Drug Congress is a multi-faceted event
|
You may also like to attend:
See more › |
comment / report a mistake | contact us | about Terrapinn | site map | privacy | T&Cs
©Terrapinn Holdings Ltd. MMX